Position in SCYX
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$9,783
+$1,799 QoQ
Shares Held
1,334
-15.5% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SCYX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Creative Planning holds $137,414,626 across 41 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RDY |
Dr Reddys Laboratories Ltd
|
1,240,848 | $17,979,887 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
28,934 | $15,677,309 | |
| 3 | VTRS |
Viatris Inc
|
920,607 | $14,619,238 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
76,818 | $12,946,905 | |
| 5 | LNTH |
Lantheus Holdings, Inc.
|
85,571 | $9,493,246 | |
| 6 | TAK |
Takeda Pharmaceutical Co Ltd
|
584,777 | $9,373,974 | |
| 7 | ZTS |
Zoetis Inc.
|
121,209 | $8,710,078 | |
| 8 | HIMS |
Hims & Hers Health, Inc.
|
225,206 | $7,807,891 |
All Filings in SCYX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,783 | 10,669 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $7,984 | 12,633 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,908 | 10,271 | Shares | Sole | 2025-11-14 | |
| 2023-09-30 | $41,819 | 18,342 | Shares | Sole | 2023-11-16 | |
| 2021-03-31 | $236,612 | 29,800 | Shares | Sole | 2021-04-30 | |
| 2020-12-31 | $188,955 | 24,700 | Shares | Sole | 2021-01-29 | |
| 2020-09-30 | $91,287 | 20,700 | Shares | Sole | 2020-11-05 | |
| 2020-06-30 | $155,457 | 207,000 | Shares | Sole | 2020-07-23 | |
| 2020-03-31 | $157,762 | 202,000 | Shares | Sole | 2020-05-05 | |
| No filing history on record for this holder in this stock. | ||||||